|  |
| --- |
| **Basic details** |

*This pre-proposal application form can either be filled in completely in English, or completely in Dutch.*

*Dit projectidee aanvraagformulier mag volledig in het Engels, of volledig in het Nederlands worden ingevuld.*

**1. Project title:**

**2. Contact details of main applicant (‘penvoerder’)**

|  |
| --- |
| **Consortium partner 1** |
| Name of the organisation |  |
| Department |  |
| Name of contact person, title(s) |  |
| Male/female/other |  |
| Position |  |
| Address for correspondence |  |
| Telephone |  |
| E-mail: |  |
| Type of organisation | *Company (for profit enterprise)/Research organisation/Non-profit enterprise/Health fund/Citizen initiative/Other* |

**3. List of consortium partners (co-applicants)**

|  |
| --- |
| **Consortium partner 2** |
| Name of the organisation |  |
| Department |  |
| Type of organisation | *Company (for profit enterprise)/Research organisation/Non-profit enterprise/Health fund/Citizen initiative/Other* |

|  |
| --- |
| **Consortium partner 3** |
| Name of the organisation |  |
| Department |  |
| Type of organisation | *Company (for profit enterprise)/Research organisation/Non-profit enterprise/Health fund/Citizen initiative/Other* |

etc.

**4. Duration of the project (min. 24 months, max. 36 months):**

|  |
| --- |
| **Project content** |

**5. Summary**

1. Brief description of the objectives, subject, key challenges, and approach (max. 300 words, including figure and table legends). How the project contributes to the goals of the Top Sector LSH should be addressed under section *8. Importance of the Project*.
2. Brief overview and description of the envisioned work packages (max. 150 words)
3. Brief description of why this consortium is capable of achieving the objectives, the degree of collaboration, and how the quadruple helix is (envisioned to be) included or represented in the consortium (200 words).
4. Brief description of the expected societal and economic impact of this project (150 words).
5. Please describe how this project realizes the first steps towards a new envisioned standard over 10 – 20 years (150 words).

**6. Research category (see Appendix A and B):**

1. Please indicate per work package the applicable type(s) of research (more than one option possible).

|  |  |  |
| --- | --- | --- |
| **Types of research** | **yes/no** | **WP** |
| 1. Fundamental research
 |  |  |
| 1. Industrial research
 |  |  |
| 1. Experimental development
 |  |  |

1. Please give an explanation of the chosen research type(s). Make use of the phrasing that has been used to define the three types of research (see Appendix A).

**7.** **Estimated budget**

Estimated budget and the requested amount of TKI-LSH PPP-Allowance for Illustration projects (minimal €350.000 and maximal €600.000).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Partner** | **Personnel costs (k€)** | **Man hours**  | **Equipment/ material costs (k€)** | **Total costs (k€)** | **Requested Funding (k€)** |
| Partner #1 |  |  |  |  |  |
| Partner #2 |  |  |  |  |  |
| Partner #3 |  |  |  |  |  |
| Etc.  |  |  |  |  |  |
| **Total**  |  |  |  |  |  |

**8. Importance of the project**

1. Please describe how the project fits within the [Knowledge and Innovation Agenda 2020-2023](https://www.health-holland.com/public/publications/kia/kennis-en-innovatieagenda-2020-2023-gezondheid-en-zorg.pdf) (max. 100 words). The KIA represents a broader scope than just the missions on pages 18-36, i.e., it is also aimed at e.g., sustainability, affordability, patient participation etc. The contribution to the missions should be described in section 8.b and 8.c.
2. Please indicate below how the project contributes to the Central Mission with a focus on decreasing health inequalities between the lowest and highest socio-economic groups (max 150 words).
* Central Mission:

 By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socio-economic groups will have decreased by 30%.

1. Please indicate below how the project contributes to one or more of the other missions of the Top Sector LSH listed below (max. 100 words):
* Mission I:

 By 2040, the burden of disease resulting from an unhealthy lifestyle and living environment will have decreased by 30%.

* Mission II:

 By 2030, the extent of care provided to people within their own living environment (rather than in health-care institutions) will be 50% more than today or such care will be provided 50% more frequently than at present.

* Mission III:

 By 2030, the proportion of people with a chronic disease or lifelong disability who can play an active role in society according to their wishes and capabilities will have increased by 25%.

* Mission IV:

 By 2030, quality of life for people with dementia will have improved by 25%.

1. Please describe if and how the project has a cross-over with one of the other [Knowledge and Innovation agendas](https://www.topsectoren.nl/missiesvoordetoekomst) and contributes to their missions (max. 100 words).
2. Please describe how the project contributes to the Health & Care Visions of the future ‘de [toekomstbeelden’](https://www.health-holland.com/sites/default/files/downloads/Toekomstbeelden%202030.pdf) (max. 100 words)

**9. Key Enabling Technologies and Methodologies**

1. Indicate on which of the Key Enabling Technologies[[1]](#footnote-2) the project applies to.

|  |  |
| --- | --- |
| **Key Enabling Technologies** | **yes/no** |
| 1. Advanced materials
 |  |
| 1. Chemical technologies
 |  |
| 1. Digital technologies
 |  |
| 1. Engineering and fabrication technologies
 |  |
| 1. Life science technologies
 |  |
| 1. Quantum technologies
 |  |
| 1. Nanotechnologies
 |  |
| 1. Photonics and light technologies
 |  |
| 1. Not applicable
 |  |

1. Describe why these Key Enabling Technologies are relevant for the project, and thus how the project helps in the application and/or development of these technologies (max. 100 words).
2. Indicate which of the Key Enabling Methodologies[[2]](#footnote-3) the project applies to.

|  |  |
| --- | --- |
| **Key Enabling Methodologies** | **yes/no** |
| 1. Vision and imagination
 |  |
| 1. Participation and co-creation
 |  |
| 1. Behaviour and empowerment
 |  |
| 1. Experimental environments
 |  |
| 1. Value creation and upscaling
 |  |
| 1. Institutional change
 |  |
| 1. System change
 |  |
| 1. Monitoring and effect measurement
 |  |

1. Describe why these Key Enabling Methodologies are relevant for the project by addressing (max. 150 words):
	1. How they are embedded in the project’s approach.
	2. How expertise on these methodologies is employed within the project (via which consortium partner or third party).
2. Describe possible collaborations with other public-private partnerships or which of these public-private partnerships are relevant for a future collaboration (see the overview on the Health˜Holland website[[3]](#footnote-4), max. 100 words).

**10. Have the consortium partners requested or received any additional grants for (the activities under one or more of the work packages of) this PPP-project?**

Yes / No

*If yes, please specify grant supplier(s), grant name(s), total amount requested/received per grant (in €) and status (applied/granted).*

|  |
| --- |
| **Statement by project coordinator** |

[ ]  By submitting this form, I declare that I have completed this form truthfully and I declare that I have informed the correct official(s) of my employing organisation of this submission.

Name:

Place:

Date:

Please note: Information provided in relation to this application will be treated confidentially by Health~Holland.

**Appendix A: Definitions of the three types of research**

**Fundamental research** means experimental or theoretical work undertaken

primarily to acquire new knowledge of the underlying foundations of phenomena

and observable facts, without any direct commercial application or use in view.

**Industrial research** means the planned research or critical investigation aimed at

the acquisition of new knowledge and skills for developing new products,

processes or services or for bringing about a significant improvement in existing

products, processes or services. It comprises the creation of components parts of

complex systems, and may include the construction of prototypes in a laboratory

environment or in an environment with simulated interfaces to existing systems as

well as of pilot lines, when necessary for the industrial research and notably for

generic technology validation.

**Experimental development** means acquiring, combining, shaping and using

existing scientific, technological, business and other relevant knowledge and skills

with the aim of developing new or improved products, processes or services. This

may also include, for example, activities aiming at the conceptual definition,

planning and documentation of new products, processes or services. Experimental

development may comprise prototyping, demonstrating, piloting, testing and

validation of new or improved products, processes or services in environments

representative of real-life operating conditions where the primary objective is to

make further technical improvements on products, processes or services that are

not substantially set. This may include the development of a commercially usable

prototype or pilot which is necessarily the final commercial product, and which is

too expensive to produce for it to be used only for demonstration and validation

purposes. Experimental development does not include routine or periodic changes

made to existing products, production lines, manufacturing processes, services

and other operations in progress, even if those changes may represent

improvements.

**Appendix B: Technology Readiness Levels**

To determine the type of research the following table of TRL levels may be of further assistance (but the definition of types of research given above prevails):

|  |  |  |
| --- | --- | --- |
| **TRL** | **Definition** | **Indication type of research\*** |
| TRL 1 | Basic principles observed | Fundamental research |
| TRL 2 | Technology concept formulated | Fundamental research |
| TRL 3 | Experimental proof of concept | Fundamental research |
| TRL 4 | Technology validated in lab | Fundamental/industrial research |
| TRL 5 | Technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies) | Industrial research |
| TRL 6 | Technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies) | Industrial research |
| TRL 7 | System prototype demonstration in operational environment | Industrial research/experimental development |
| TRL 8 | System complete and qualified | Beyond the scope of the PPP Allowance Regulation |
| TRL 9 | Actual system proven in operational environment (competitive manufacturing in the case of key enabling technologies; or in space) | Beyond the scope of the PPP Allowance Regulation |

1. <https://www.hollandhightech.nl/kia-sleuteltechnologieen> [↑](#footnote-ref-2)
2. <https://www.clicknl.nl/onderzoeksagenda-kems-missiegedreven-innovatie/> [↑](#footnote-ref-3)
3. <https://www.health-holland.com/public-private-partnerships> [↑](#footnote-ref-4)